APhA Urges FDA to Delay Peptide Substances Approval Citing Safety Risks — American Pharmacists Association (APhA)

Event summary

APhA submitted comments to FDA on July 17, 2026 urging caution in reviewing peptide substances for the Section 503A Bulks List.
The association highlighted risks from unregulated online markets selling peptide products with potential contamination and inaccurate dosing.
APhA supports FDA's recommendation not to add nominated peptides to the Bulks List due to insufficient clinical evidence.
The organization called for stronger patient and healthcare professional education on peptide therapies.

The big picture

APhA's intervention highlights the tension between innovation in peptide therapies and the need for robust regulatory safeguards. The growing black market for unregulated peptides poses significant patient safety risks, potentially influencing FDA's approach to compounding pharmacy regulations. This development comes as demand for personalized medicine continues to rise, creating a complex landscape for both regulators and healthcare providers.

What we're watching

Regulatory Timing: Whether FDA will accelerate or delay its review process for peptide substances in response to APhA's concerns.
Market Dynamics: How the growth of unregulated peptide markets may impact FDA's regulatory approach and industry standards.
Clinical Research: The pace at which peer-reviewed research will establish sufficient safety and efficacy data for these peptides.